Opko chief, ex-Teva chairman Phillip Frost charged with share manipulation in U.S. ■ Generation Capital takes 50% stake in power plant operator Rapac Energy ■ TASE ends lower after long holiday weekend
Teva offers to buy back $400 million in bonds ■ RADA cashes in on drone-threat fears ■ TASE closes in the red, dragged down by Wall Street
Teva Pharmaceutical's version of Mylan NV's EpiPen to provide 'lower-cost option' for patients 'living with severe allergies,' FDA commissioner says
Berkshire Hathaway also massively invested more in Goldman Sachs and Apple
The pharmaceutical company is in a $28.4 billion debt. Analysts says the company still lacks growth drivers
Trouble drugmaker offers rosier outlook for rest of year, despite delay in approval for key migraine treatment
Elsztain enlists unions to help block sale of Clal Insurance ■ Medical-marijuana shares get lift as lawmakers express support for exports ■ Shares end mixed as bank stage powerful rally
U.S. President Trump’s obsession with the stock market as a gauge of his success augurs ill, and Israel needs to rethink its own strategy
Gilat finally swings to profit ■ Leumi turns bearish on Leviathan ■ Stocks end mixed
Nearly half went to three managers leading company during failed Actavis acquisition